Zhao Hui, Yang Cheng-E, Liu Tian, Zhang Ming-Xia, Niu Yan, Wang Ming, Yu Jun
Clinical Experimental Center, Xi'an Engineering Technology Research Center for Cardiovascular Active Peptides, the Affiliated Xi'an International Medical Center Hospital, Northwest University, Xi'an, Shaanxi, China.
Faculty of Life Science and Medicine, Northwest University, Xi'an, Shaanxi, China.
Front Microbiol. 2023 Jul 27;14:1207132. doi: 10.3389/fmicb.2023.1207132. eCollection 2023.
Diabetic nephropathy (DN) is a severe microvascular complication of diabetes, which increases the risk of renal failure and causes a high global disease burden. Due to the lack of sustainable treatment, DN has become the primary cause of end-stage renal disease worldwide. Gut microbiota and its metabolites exert critical regulatory functions in maintaining host health and are associated with many pathogenesis of aging-related chronic diseases. Currently, the theory gut-kidney axis has opened a novel angle to understand the relationship between gut microbiota and multiple kidney diseases. In recent years, accumulating evidence has revealed that the gut microbiota and their metabolites play an essential role in the pathophysiologic processes of DN through the gut-kidney axis. In this review, we summarize the current investigations of gut microbiota and microbial metabolites involvement in the progression of DN, and further discuss the potential gut microbiota-targeted therapeutic approaches for DN.
糖尿病肾病（DN）是糖尿病严重的微血管并发症，会增加肾衰竭风险并造成全球疾病负担加重。由于缺乏可持续的治疗方法，DN已成为全球终末期肾病的主要病因。肠道微生物群及其代谢产物在维持宿主健康方面发挥着关键的调节功能，且与许多衰老相关慢性病的发病机制有关。目前，肠-肾轴理论为理解肠道微生物群与多种肾脏疾病之间的关系开辟了新视角。近年来，越来越多的证据表明，肠道微生物群及其代谢产物通过肠-肾轴在DN的病理生理过程中发挥重要作用。在本综述中，我们总结了目前关于肠道微生物群和微生物代谢产物参与DN进展的研究，并进一步讨论了针对DN的潜在肠道微生物群靶向治疗方法。
